Kazia Therapeutics Ltd ADR
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KZIA research report →
Range $25 – $40
Price Chart
About the company
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer.
- CEO
- John Friend
- IPO
- 1999
- Employees
- 6
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on KZIA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.00M
- P/E
- -1.29
- PEG
- -0.01
- P/S
- 1093.33
- P/B
- 0.89
- EV/EBITDA
- 2.63
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -92086.45%
- Net Margin
- -113004.58%
- ROE
- -116.86%
- ROIC
- -36.21%
Latest fiscal year · YoY change
- Revenue
- $42.00K-98.2%
- Gross Profit
- $42.00K-98.2%
- Op Income
- $-14,217,000
- Net Income
- $-20,702,000+22.7%
- EPS
- $-18.90+65.6%
- OCF Growth
- -38.6%
- FCF Growth
- -38.6%
- 52W High
- $17.40
- 52W Low
- $4.86
- 50D MA
- $12.02
- 200D MA
- $10.47
- Beta
- 2.27
- RSI (14)
- 34
- Avg Volume
- 264.52K
No earnings-call transcripts are available for KZIA yet.
- Free Float
- 98.6%
- Shares Outstanding
- 1.62M
- Float Shares
- 1.60M
of shares held by institutions
23 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Boxer Capital Management, LLC | 560.00K | ▲ 560.00K |
| Flputnam Investment Management Co | 414.96K | ▲ 272.49K |
| Bleichroeder LP | 400.00K | 0 |
| Ikarian Capital, LLC | 396.20K | ▲ 396.20K |
| Dauntless Investment Group, LLC | 354.21K | ▲ 274.38K |
| Stonepine Capital Management, LLC | 345.18K | 0 |
| Point72 Asset Management, L.P. | 200.30K | ▲ 300 |
| Ensign Peak Advisors, Inc | 110.78K | ▲ 110.78K |
| Millennium Management LLC | 101.38K | ▲ 101.38K |
| Ubs Group AG | 81.09K | ▲ 67.16K |
| J. Goldman & Co LP | 68.49K | ▲ 68.49K |
| Adar1 Capital Management, LLC | 61.55K | ▲ 61.55K |
Held by 3 ETFs
Biggest fund positions in KZIA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 8, 26 | Coffey Steven R. S. | other | 100,000 |
| Jan 8, 26 | Friend John E. II | other | 500,000 |
| Jan 8, 26 | Friend John E. II | other | 150,000 |
| Jan 8, 26 | Bonacorda Jeffrey | other | 150,000 |
| Jan 8, 26 | Davidson Ebru | other | 100,000 |
| Jan 8, 26 | Cain David | other | 100,000 |
| Jan 8, 26 | APPLE ROBERT F | other | 75,000 |
| Jun 19, 26 | Levine James E. | other | 200,000 |
| Jun 19, 26 | Rao Sudha | other | 250,000 |
| Jun 1, 26 | Levine James E. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KZIA coverage
Recent articles, reports, and earnings notes.
No research on KZIA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KZIA report →Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
prnewswire.com · Sep 22
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
prnewswire.com · Sep 9
Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript
seekingalpha.com · Sep 4
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
prnewswire.com · Sep 1
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
prnewswire.com · Sep 1
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
prnewswire.com · Aug 31
Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data
seekingalpha.com · Aug 31
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
prnewswire.com · Aug 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.